Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease.

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington Disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PBT 2 (Primary)
  • Indications Huntington's disease
  • Focus Adverse reactions
  • Acronyms Reach2HD
  • Sponsors Alterity Therapeutics

Most Recent Events

  • 18 Oct 2016 According to Prana Biotehnology media release, the cognitive results of this study were presented at the American Neurological Association (ANA) Annual Meeting.
  • 27 Apr 2015 According to Prana Biotehnology media release, US Food and Drug Administration granted PBT2 orphan drug status for the treatment of Huntington disease and European Medicines Agencys Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).
  • 10 Dec 2013 Results are expected to be reported in the first quarter of 2014, according to a Prana Biotherapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top